Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | New horizons in CML

Gianantonio Rosti • 13 Jun 2019
EHA 2019
Chronic Myeloid Leukemia Leukemia Asciminib Interferon

Gianantonio Rosti, MD, Institute of Hematology ‘Seragnoli’, Bologna, Italy, discusses new treatments in chronic myeloid leukemia (CML). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Gianantonio Rosti

2:17
Current CML treatments: which TKI to choose?
Gianantonio Rosti • 13 Jun 2019
1:55
Long-term monitoring, adherence & endpoints in CML
Gianantonio Rosti • 13 Jun 2019
4:33
Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
Gianantonio Rosti • 12 Jun 2015

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals